Previous 10 | Next 10 |
AUSTIN, Texas, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biolog...
The stocks of Magenta Therapeutics (NASDAQ: MGTA) and Molecular Templates (NASDAQ: MTEM) bolted skywards last week, to the tune of 39% and 28% respectively. Cutting-edge gene-editing therapies, chimeric antigen receptor T-cell (CAR-T) treatments, and stem cell transplants all require pr...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 132 weeks of public selections as part of this ongoing live forward-testing. In...
Gainers: Wah Fu Education Group (NASDAQ: WAFU ) +203% . More news on: Wah Fu Education Group Limited, Hepion Pharmaceuticals, Inc., Stage Stores, Inc., Stocks on the move, Read more ...
Molecular Templates (NASDAQ: MTEM ) prices its public offering of 6.0M common shares at $8.00 per share and 250 Series A convertible preferred shares at $8,000 per share, for expected gross proceeds of $50M. More news on: Molecular Templates, Inc., Healthcare stocks news, Stocks on the m...
AUSTIN, Texas, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM) (the “Company” or “Molecular”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary engineered toxin...
AUSTIN, Texas, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM) (the “Company” or “Molecular”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary engineered toxin...
Vertex Pharmaceuticals (NASDAQ: VRTX ) will collaborate with Molecular Templates (NASDAQ: MTEM ) to discover and develop novel targeted conditioning regimens aimed at enhancing the process of hematopoietic stem cell transplantation (HSCT), including transplants conducted as part of treatme...
-Molecular Templates to receive $38 million upfront payment, including equity investment, with potential for additional milestone and royalty payments on future sales- BOSTON and AUSTIN, Texas, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Molec...
EDMONTON, Alberta, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Translational Research in Oncology (TRIO), a global academic clinical research organization, today announced enrolment of the first patient in a Phase I study with its partner Molecular Templates (Nasdaq: MTEM). This Phase I first-in...
News, Short Squeeze, Breakout and More Instantly...
Molecular Templates Inc. Company Name:
MTEM Stock Symbol:
NASDAQ Market:
Molecular Templates Inc. Website:
AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineere...